Finally, NYHA class was not available and brain natriuretic peptide was not checked in the many patients, so it is possible that a small number of patients with a secondary diagnosis of heart failure had NYHA Class I symptoms, suggesting MRA therapy may not be strictly indicated for these patients according to current guidelines [7, 8, 26]. This evidence concerns the gene NPPB and heart failure.